相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older
Min Hwan Kim et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Randomized Open Labe Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)
In Hae Park et al.
CANCER RESEARCH AND TREATMENT (2019)
A phase 2 study of glembatumumab vedotin, an antibody-drug conjugate targeting glycoprotein NMB, in patients with advanced melanoma
Patrick A. Ott et al.
CANCER (2019)
Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
A. Bardia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity
Gordana Maric et al.
ONCOGENE (2019)
Phase II trial of the glycoprotein non-metastatic B-targeted antibody-drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group
Lisa M. Kopp et al.
EUROPEAN JOURNAL OF CANCER (2019)
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
G. von Minckwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark Robson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Yukari Okita et al.
SCIENCE SIGNALING (2017)
The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB
Yukari Okita et al.
SCIENCE SIGNALING (2017)
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review
Garrett K. Berger et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Identification of Novel Agents for the Treatment of Brain Metastases of Breast Cancer
Vinay K. Venishetty et al.
CURRENT CANCER DRUG TARGETS (2017)
RESILIENCE: Phase III Randomized, Double-Blind Trial Comparing Sorafenib With Capecitabine Versus Placebo With Capecitabine in Locally Advanced or Metastatic HER2-Negative Breast Cancer
Jose Baselga et al.
CLINICAL BREAST CANCER (2017)
Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection
Brian D. Lehmann et al.
PLOS ONE (2016)
Activity of T-DM1 in Her2-positive breast cancer brain metastases
Rupert Bartsch et al.
CLINICAL & EXPERIMENTAL METASTASIS (2015)
EMERGE: A Randomized Phase II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Advanced Glycoprotein NMB-Expressing Breast Cancer
Denise A. Yardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
CD30 Downregulation, MMAE Resistance, and MDR1 Upregulation Are All Associated with Resistance to Brentuximab Vedotin
Robert Chen et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA
I. E. Krop et al.
ANNALS OF ONCOLOGY (2015)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Advanced Melanoma
Patrick A. Ott et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase I/II Study of the Antibody-Drug Conjugate Glembatumumab Vedotin in Patients With Locally Advanced or Metastatic Breast Cancer
Johanna Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Breast cancer brain metastases responding to primary systemic therapy with T-DM1
Rupert Bartsch et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Beyond taxanes: the next generation of microtubule-targeting agents
Javier Cortes et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large phase III clinical studies.
HS Rugo et al.
CANCER RESEARCH (2010)
Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer
April A. N. Rose et al.
CLINICAL CANCER RESEARCH (2010)
Is Capecitabine Efficacious in Triple Negative Metastatic Breast Cancer?
A. A. Kotsori et al.
ONCOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Osteoactivin promotes breast cancer metastasis to bone
April A. N. Rose et al.
MOLECULAR CANCER RESEARCH (2007)
分享论文
